-
-
-
-
-
-
-
Theravance Biopharma (TBPH) PT Lowered to $21 at BTIG following trial miss
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Theravance Biopharma (TBPH)
-
-
-
-
-
-
-
Theravance Biopharma (TBPH) Misses Q3 EPS by 3c, provides guidance
-
-
-
-
-
-
-
After-Hours Stock Movers 08/23: (CARA) (PANW) (BXC) Higher; (TBPH) (MARK) Lower (more...)
416,808 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

